(RLFTF) – Accesswire
-
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
-
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
-
Relief Therapeutics Announces CEO Transition
-
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
-
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
-
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
-
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
-
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
-
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
-
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Back to RLFTF Stock Lookup
